<DOC>
	<DOCNO>NCT01292655</DOCNO>
	<brief_summary>The purpose study identify safe tolerable dose BMS-906024 subject advance metastatic solid tumor longer respond relapsed standard therapy .</brief_summary>
	<brief_title>Study Evaluate Safety Tolerability IV Doses BMS-906024 Subjects With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects advance metastatic solid tumor ( nonhematologic refractory relapse standard therapy know effective treatment dose escalation Subjects squamous nonsmall cell lung cancer triplenegative breast cancer solid tumor type Notch activation demonstrate ( pancreatic , ovarian melanoma ) dose expansion Biopsy accessible tumor ( may waive certain circumstance ) Life expectancy least 3 month Eastern Cooperative Oncology Group ( ECOG ) 01 Adequate organ bone marrow function Infection Elevated triglycerides Gastrointestinal ( GI ) disease increase risk diarrhea [ e.g . inflammatory bowel disease ( IBD ) ] Taking medication know increase risk Torsades De Pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>